Q
Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

24,258 signal articles · 40 in last 24h · 115,255 total before filter · latest 2h ago
40last 24h
1803last 7d
299● bullish (7d)
171● bearish (7d)
205publishers
AllMacro322Earnings851M&A104Regulatory25Product16Analyst25
✕ clear all filtersticker: IEXsentiment: neutralSentiment:bullishneutralbearishshow all (incl. clickbait)
IDEX Q2 Earnings Call Highlights
MarketBeat16d agoneutral
IDEX Q2 Earnings Call Highlights

IDEX (NYSE:IEX) reported second-quarter 2026 results that exceeded its expectations, supported by growth in its Health & Science Technologies segment, stronger orders and operational execution. The company raised its full-year outlook for organic sales growth, adjusted EBITDA margin and adjusted

IDEX Q1 Earnings Call Highlights
MarketBeat107d agoneutral
IDEX Q1 Earnings Call Highlights

IDEX (NYSE:IEX) reported first-quarter 2026 results that management said came in above expectations, supported by growth in its targeted “advantage markets” and continued application of the company’s 80/20 operating philosophy. Quarterly performance and orders President and CEO Eric Ashleman said I

IDEX (IEX) Q1 2026 Earnings Call Transcript
Motley Fool108d agoneutral
IDEX (IEX) Q1 2026 Earnings Call Transcript

IDEX delivered a strong first quarter and continue to see our growth strategies gain traction as we expand and integrate capabilities in targeted advantaged markets powered by 8020. In the first quarter, IDEX delivered organic sales growth of 5% and adjusted EBITDA margin of 26%, which reflects a margin expansion of 50 basis points year-over-year. Strength was most pronounced in our Health & Science Technologies, or HST segment, where secular drivers continue to fuel growth across high-value applications in data center, semiconductor and space and defense markets.